Document is current

Article History

Received: 22 August 2025

Accepted: 9 February 2026

First Online: 11 April 2026

Declarations

:

: The study was conducted in compliance with the international ethics guidelines, including the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines for Good Clinical Practice (GCP), as well as all applicable laws, rules, and regulations. The study was approved by the Institutional Review Board at each site, and written informed consent was obtained from all study participants prior to their enrollment.

: Not applicable.

: Marina Konopleva reports receiving consultancy fees from AbbVie, Forty Seven, Precision BioSciences, Gilead Sciences, Genentech, Janssen, Sanofi, MEI Pharma, Daiichi Sankyo Pharmaceutical, AstraZeneca Co., and Menarini; research funding from AbbVie, Allogene Therapeutics, Cellectis, Forty Seven, Gilead Sciences, Genentech, Sanofi, MEI Pharma, Rafael Pharmaceuticals, Daiichi Sankyo Pharmaceutical, AstraZeneca Co., Menarini, and Precision BioSciences; and holds shares/stocks in Reata Pharmaceuticals. Ioannis Mantzaris reports having received honoraria from Kite Pharma. Reports participation in advisory board for Syndax. Abhishek Maiti reports receiving research funding from Celgene, Lin BioScience. Krishna Gundabolu reports receiving consultancy fees from Bristol-Myers Squibb, CTI BioPharma Corp, Blueprint Medicines, Sanofi Aventis GmbH, Spark Therapeutics. Reports participation advisory bords for Incyte and SOBI. Vijaya Raj Bhatt reports participating in the Safety Monitoring Committee for Protagonist, serving as a member of the National Comprehensive Cancer Network Acute Myeloid Leukemia Panel, as an associate editor for the journal Current Problems in Cancer, and as a contributor for BMJ Best Practice and receiving consulting fees from Jazz, research funding (institutional) from Cynata Therapeutics, MEI Pharma, Actinium Pharmaceutical, Sanofi U.S. Services, AbbVie, Pfizer, Incyte, Jazz, and National Marrow Donor Program, and drug support (institutional) from Chimerix for a trial. Naval Daver reports receiving consultancy fees from Bristol-Myers Squibb, Daiichi, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Jazz, Syndax, Sumitomo, Kura, AROG, Servier, Shattuck labs, Sanofi, Arcellx, Caribou, Debiopharm, Aptos, Astra-Zeneca, StemLine, VincerX; research funding from Hanmi, Trovagene, FATE, Novimmune, Glycomimetics, BMS, Astellas, Daiichi, Abbvie, Immunogen, Shattuck labs, Sanofi, Arcellx, Caribou, Debiopharm, Aptos, Astra-Zeneca, StemLine, VincerX, Nerviano, FATE therapeutics, Sumitomo, Kura Jolie Schafer, Kyle Jensen, Rao Saleem, Yi Li, Agata Drewniak, Pierre Bay, Winston Huh, Ozlem Yildirim, and Sarah Cooley are employee of Sanofi and may hold stocks and/or stock options.